No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines.

Yalcinkaya A, Cavalli M, Cederholm A, Aranda-Guillén M, Behere A, Mildner H, Lakshmikanth T, Gonzalez L, Mugabo CH, Johnsson A, Ekwall O, Kämpe O, Bensing S, Brodin P, Hallberg P, Wadelius M, Landegren N

NPJ Vaccines 9 (1) 42 [2024-02-22; online 2024-02-22]

Type I interferons act as gatekeepers against viral infection, and autoantibodies that neutralize these signaling molecules have been associated with COVID-19 severity and adverse reactions to the live-attenuated yellow fever vaccine. On this background, we sought to examine whether autoantibodies against type I interferons were associated with adverse events following COVID-19 vaccination. Our nationwide analysis suggests that type I interferon autoantibodies were not associated with adverse events after mRNA or viral-vector COVID-19 vaccines.

Autoimmunity and Serology Profiling [Service]

PubMed 38388530

DOI 10.1038/s41541-024-00829-9

Crossref 10.1038/s41541-024-00829-9

pmc: PMC10883980
pii: 10.1038/s41541-024-00829-9

Publications 9.5.0